What homologous use actually means
FDA defines homologous use, at 21 CFR 1271.3(c), as the repair, reconstruction, replacement, or supplementation of a recipient's tissue with an HCT/P that performs the same basic function in the recipient as it performed in the donor. The test is narrow on purpose: same basic function, not merely the same tissue of origin or the same general anatomical category.
This is why two products derived from similar donor tissue can land on opposite sides of the line. The relevant question is never 'is this umbilical cord tissue,' it is whether this specific product, used in this specific way, performs the same basic function it performed for the donor.
Why homologous use hct/p status outweighs how the tissue was processed
21 CFR 1271.10(a) lists four independent criteria for staying under section 361, and homologous use is one of them, not a tiebreaker among the others. A product can be minimally manipulated, free of combination with other articles, and have no systemic effect, and still fail to qualify for section 361 if its intended use is not homologous.
That is the practical reason marketing claims function as a regulatory question rather than a compliance afterthought. A processing description can be entirely accurate and a label can still describe a use that pushes the product into the drug and biologic pathway under section 351.
How FDA actually determines intended use
Intended use is established by the totality of evidence surrounding a product, not by a single sentence on a label. FDA looks to labeling and package insert language, oral and written claims made by the company or its representatives, the circumstances of distribution, and advertising.
The 2026 warning letters sent to distributors of perinatal and exosome products illustrate how far this reaches in practice. FDA cited website content and social media posts in those cases, treating a company's own marketing, and in some cases its affiliates' marketing, as direct evidence of what the product was intended to do.
- Product labeling and the written insert that ships with the lot
- Website and landing page claims, including comparison and condition-specific pages
- Social media posts made by the company or its sales representatives
- Claims made by resellers, affiliates, or clinics the distributor supplies
- The clinical setting and manner in which the product is actually used
Why a research-use-only label does not settle the question
A 'research use only' or 'not for clinical use' disclaimer is sometimes treated by sellers as a safe harbor. It is not reliable as one. When other marketing, including a company's own website or an affiliate's promotion, points toward clinical use, FDA's recent enforcement has not treated the disclaimer as controlling.
The practical takeaway is that a disclaimer buried in fine print does not offset a landing page, a sales call, or a social post describing the product as something it is actually being used for clinically.
What homologous use looks like for perinatal tissue and exosome products
WJ products are offered under the supplier's HCT/P framework. Whether a specific intended use qualifies under 21 CFR 1271.10 is for the clinic and its counsel to determine for that use, not a default inherited from the tissue type.
Exosome products are generally regulated as biologic drugs under section 351. FDA states there are no FDA-approved exosome products, and purchase and clinical-use decisions for them belong to the physician, together with their own regulatory counsel.
Questions worth settling before anything gets published
Before a distributor or clinic publishes a claim about a perinatal or exosome product, it is worth confirming internally what basic function the product is being described as performing, whether that function matches the donor tissue's original role, and whether every channel describing the product, website, social, sales scripts, and affiliate content, says the same thing.
This overview is educational and is not legal advice. A homologous use determination for a specific product and a specific intended use should go through FDA regulatory counsel. These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
What is the legal definition of homologous use?+
Under 21 CFR 1271.3(c), homologous use means the HCT/P performs the same basic function in the recipient that it performed in the donor. The test focuses on function, not on the tissue's origin or general category.
Can a product be minimally manipulated and still fail the homologous use test?+
Yes. The four criteria in 21 CFR 1271.10(a) are independent of each other. A product can satisfy minimal manipulation and still be regulated outside section 361 if its intended use is not homologous.
Does a research-use-only disclaimer protect a distributor from an intended-use finding?+
Not reliably. Recent FDA warning letters show the agency looking past RUO disclaimers when other marketing, including a company's own website or social content, describes or implies clinical use.
Who is responsible for making sure marketing matches a homologous use claim, the supplier or the clinic?+
Both. FDA's intended-use analysis applies to a distributor's marketing and to a clinic's own website, consult materials, and social content independently, so each party carries its own exposure.